which company makes semaglutide Hims & Hers deal with Novo in obesity strategy shift Novo Nordisk - Wikipedia

Our plan is for you to lose your unwanted weight while combining the medication with other lifestyle interventions, such as diet and exercise

Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes-2025

Understanding the actual evidence versus rare occurrences helps set realistic expectations and distinguishes true medication effects from coincidental symptoms

Incorporate regular physical activity, aiming for at least 150 minutes of moderate exercise per week

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for managing type 2 diabetes (under the brand name Ozempic) and chronic weight management (as Wegovy)

Those experiencing ongoing digestive symptoms may find that Wegovy's gastrointestinal side effects are more pronounced or difficult to tolerate